Close Menu

Asian Cancer Research Group

The Asian Cancer Research Group, led by Pfizer, Eli Lilly, and Merck, has used whole-genome sequencing to identify recurrent, druggable mutations in hepatocellular carcinoma.

NEW YORK (GenomeWeb News) – A pair of studies in the early, online version of Nature Genetics are highlighting the types of genetic mutations that underlie the liver cancer hepatocellular carcinoma, including forms of the disease related to hepatitis B and hepatitis C virus infection.

Recently, Mao Mao, a research fellow at Pfizer Oncology Research who is working on several different cancer sequencing projects, spoke to In Sequence about the company's use of sequencing in drug development and the hurdles that still remain in implementing the technology in pharmaceutical research.

Through the formation of the Asian Cancer Research Group, Eli Lily, Merck, and Pfizer have also committed "to create one of the most extensive pharmacogenomic cancer databases known to date."

University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.

A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.

Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.

In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.